Listed by the USPTO as LANDSMAN, ROBERT S
Tech Center 1600 • Art Units: 1618 1643 1647 1681 1682
This examiner grants 81% of resolved cases
LANDSMAN, ROBERT S is assigned to tech center 1600 and art unit 1618. The profile includes 1277 resolved cases, an 81.4% allowance rate, and a median of 796 days to allowance.
The interview lift is 13.0%, showing a positive association with the recorded allowance outcome. The listed companies are Chugai Seiyaku Kabushiki Kaisha, Imperial College Innovations Limited, and Boehringer Ingelheim International GmbH. The leading firms are JMB Davis Ben-David, Nixon Peabody LLP, and BakerHostetler. The large resolved-case record provides substantial context for prosecution planning.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18579526 | IDENTIFICATION OF COMMON TUMOR-SPECIFIC T CELL RECEPTORS AND ANTIGENS | Non-Final OA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH |
| 18481673 | RECOMBINANT LIGASE COMPOSITION AND USES THEREOF | Non-Final OA | 10x Genomics, Inc. |
| 18482223 | HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18544247 | GENE THERAPY TREATMENT OF ATRIAL FIBRILLATION | Non-Final OA | Northwestern University |
| 18702227 | FC VARIANTS HAVING IMPROVED PH-DEPENDENT FCRN BINDING CAPACITY AND FCRIIIA BINDING SELECTIVITY | Non-Final OA | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION |
| 18535068 | FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME | Final Rejection | AMGEN INC. |
| 18595973 | ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18289627 | ANTI-DDR2 ANTIBODIES AND USES THEREOF | Final Rejection | Chugai Seiyaku Kabushiki Kaisha |
| 18287556 | CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS | Non-Final OA | Imperial College Innovations Limited |
| 18287542 | CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELLS | Non-Final OA | Imperial College Innovations Limited |
| 18555214 | METHODS TO DETERMINE TREATMENT EFFICACY WITH GAMMA-DELTA T CELLS | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18691384 | AMINOPEPTIDASE N-SPECIFIC MONOCLONAL ANTIBODIES AND USES THEREOF | Non-Final OA | Universiteit Gent |
| 18615679 | CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS | Non-Final OA | Viela Bio, Inc. |
| 18292922 | NOVEL ANTI-SIRPA ANTIBODIES | Non-Final OA | ELPISCIENCE BIOPHARMA, LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy81.4% of resolved applications examined by Robert S Landsman were allowed (1,277 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +13.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Robert S Landsman took 796 days on average from filing to allowance.
Robert S Landsman examines applications in Art Unit 1618 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
